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Abstract
Drug allergy encompasses a spectrum of immunologically-mediated hypersensitivity reactions with varying
mechanisms and clinical presentations. This type of adverse drug reaction (ADR) not only affects patient quality of
life, but may also lead to delayed treatment, unnecessary investigations, and even mortality. Given the myriad of
symptoms associated with the condition, diagnosis is often challenging. Therefore, referral to an allergist
experienced in the identification, diagnosis and management of drug allergy is recommended if a drug-induced
allergic reaction is suspected. Diagnosis relies on a careful history and physical examination. In some instances, skin
testing, graded challenges and induction of drug tolerance procedures may be required.
The most effective strategy for the management of drug allergy is avoidance or discontinuation of the offending
drug. When available, alternative medications with unrelated chemical structures should be substituted. Cross-
reactivity among drugs should be taken into consideration when choosing alternative agents. Additional therapy
for drug hypersensitivity reactions is largely supportive and may include topical corticosteroids, oral antihistamines
and, in severe cases, systemic corticosteroids. In the event of anaphylaxis, the treatment of choice is injectable
epinephrine. If a particular drug to which the patient is allergic is indicated and there is no suitable alternative,
induction of drug tolerance procedures may be considered to induce temporary tolerance to the drug.
This article provides a backgrounder on drug allergy and strategies for the diagnosis and management of some of
the most common drug-induced allergic reactions, such allergies to penicillin, sulfonamides, cephalosporins,
radiocontrast media, local anesthetics, general anesthetics, acetylsalicylic acid (ASA) and non-steroidal anti-
inflammatory drugs.
Introduction
Adverse drug reactions (ADRs) are defined as any harm-
ful or unintended reaction to a drug that occurs at doses
used for prevention, diagnosis, or treatment [1]. ADRs
a r ec o m m o ni ne v e r y d a yc l i nical practice, affecting
between 15-25% of patients; serious reactions occur in
7-13% of patients [2,3].
ADRs are classified as either predictable reactions that
may occur in anyone (type A) or unpredictable reactions
that occur in only susceptible individuals (type B) (see
Table 1). Predictable reactions are the most common
type of ADR and are usually dose dependent and related
to the known pharmacologic actions of the drug (e.g.,
side effects, overdose, drug interactions). Unpredictable
reactions occur in approximately 20-25% of patients
who experience ADRs; these reactions are generally
unrelated to the pharmacologic actions of the drug
[1,4,5].
Drug allergy is one type of unpredictable ADR that
encompasses a spectrum of immunologically-mediated
hypersensitivity reactions with varying mechanisms and
clinical presentations [1]. It accounts for approximately
5-10% of all ADRs [6]. Pseudoallergic reactions (also
known as non-allergic or non-immune-mediated reac-
tions) represent another type of unpredictable ADR.
These reactions are often indistinguishable from true
immunologically mediated allergic reactions, but they
lack immunological specificity.
Drug allergy not only affects patient quality of life, but
may also lead to delayed treatment, use of suboptimal
alternate medications, unnecessary investigations and
even death. Furthermore, the identification of drug
allergy is challenging given the myriad of symptoms and
clinical presentations associated with the condition.
Therefore, if a drug-induced allergic disorder is sus-
pected, consultation with an allergist experienced in the
identification, diagnosis and management of drug allergy
is recommended. This article will provide an overview
of the mechanisms and risk factors for drug allergy, as
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agement of some of the most common drug-induced
allergic disorders.
Mechanisms
Immune-mediated allergic reactions to drugs are classi-
fied according to Gell and Coombs’ classification system,
which describes the predominant immune mechanisms
involved in these reactions. This classification system
includes: immediate-type reactions mediated by immu-
noglobulin E (IgE) antibodies (type I), cytotoxic reac-
tions mediated by immunoglobulin G (IgG) or
immunoglobulin M (IgM) antibodies (type II), immune-
complex reactions (type III), and delayed-type hypersen-
sitivity reactions mediated by cellular immune mechan-
isms, such as the recruitment and activation of T cells
(type IV) [7-9]. The mechanisms, clinical manifestations,
and timing of these immune reactions are summarized
in Table 2.
Unlike immune-mediated drug reactions, pseudoaller-
gic reactions are not associated with the production of
antibodies or sensitized T cells, but are often clinically
indistinguishable from drug hypersensitivity reactions.
During these reactions, the drug has the ability, via its
chemistry or pharmacology, to directly stimulate the
release or activation of inflammatory mediators such as
histamine (from mast cells, basophils), prostaglandins,
leukotrienes, or kinins. Non-steroidal anti-inflammatory
drugs (NSAIDs), narcotics, and angiotensin-converting
enzyme (ACE) inhibitors are common causes of these
non-allergic reactions [5,10,11].
Risk factors
Factors associated with an increased risk of developing a
drug allergy include age, gender, genetic polymorphisms,
certain viral infections and drug-related factors (e.g., fre-
quency of exposure, route of administration, molecular
weight) (see Table 3). Drug allergy typically occurs in
young and middle-aged adults, and is more common in
women than men. Genetic polymorphisms in the
human leukocyte antigen (HLA; a gene product of the
major histocompatibility complex) as well as viral infec-
tions such as human immunodeficiency virus (HIV) and
the Epstein-Barr virus (EBV), have also been linked to
an increased risk of developing immunologic reactions
to drugs. Susceptibility to drug allergy is influenced by
genetic polymorphisms in drug metabolism. In addition,
topical, intramuscular, and intravenous routes of admin-
istration are more likely to cause allergic drug reactions
than oral administration; while intravenous administra-
tion is associated with more severe reactions. Prolonged
high doses or frequent doses are more likely to lead to
hypersensitivity reactions than a large single dose.
Furthermore, large macromolecular drugs (e.g., insulin
Table 1 Classification of adverse drug reactions [1,4,5]
Type A:
Predictable
Type B: Unpredictable
￿ Drug overdose
￿ Secondary drug
effects
￿ Side effects
￿ Drug interactions
￿ Drug allergy: an immunologically mediated ADR
￿ Pseudoallergic (non-allergic): a reaction with the same clinical manifestations as an allergic reaction, but that lacks
immunological specificity
￿ Drug intolerance: an undesirable pharmacologic effect that occurs at low and sometimes sub-therapeutic doses of the drug
that are not caused by underlying abnormalities of metabolism or drug excretion
￿ Drug idiosyncrasy: an abnormal/unexpected effect, usually caused by underlying abnormalities of metabolism, excretion, or
bioavailability
ADR: adverse drug reaction
Table 2 Classification of allergic drug reactions: mechanisms, clinical manifestations, and timing of reactions. [7-9]
Immune
reaction
Mechanism Clinical manifestations Timing of reaction
Type I (IgE-
mediated)
Drug-IgE complex binding to mast cells with release of histamine,
inflammatory mediators
Anaphylaxis*, urticaria*,
angioedema*,
bronchospasm*
Minutes to hours
after drug exposure
Type II
(cytotoxic)
Specific IgG or IgM antibodies directed at drug-hapten coated cells Anemia, cytopenia,
thrombocytopenia
Variable
Type III (immune
complex)
Tissue deposition of drug-antibody complexes with complement activation
and inflammation
Serum sickness, vasculitis,
fever, rash, arthralgia
1 to 3 weeks after
drug exposure
Type IV (delayed,
cell mediated)
MHC presentation of drug molecules to T cells with cytokine and
inflammatory mediator release; may also be associated with activation and
recruitment of eosinophils, monocytes, and neutrophils
Contact sensitivity
Skin rashes, organ-tissue
damage
2 to 7 days after
drug exposure
IgE: immunoglobulin E; IgG: immunoglobulin G; IgM: immunoglobulin G; MHC: major histocompatibility complex
*These reactions may also be non-immunologically mediated.
Adapted from Riedl et al., 2003.
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Page 2 of 8or horse antisera) or drugs that haptenate (bind to tissue
or blood proteins and elicit an immune response), such
as penicillin, are also associated with a greater likelihood
of causing hypersensitivity reactions. Although atopic
patients do not have an increased risk for drug allergy,
they are at increased risk for serious allergic reactions
[4,6,12-15].
Diagnosis
The diagnosis of drug allergy requires a thorough history
and the identification of physical findings and symptoms
that are compatible with drug-induced allergic reactions.
Depending on the history and physical examination
results, diagnostic tests such as skin testing, graded chal-
lenges and induction of drug tolerance procedures may
also be required. [1,4,6,15] Therefore, if drug allergy is sus-
pected, evaluation by an allergist experienced in these
diagnostic procedures is recommended.
History
Evaluation of the patient with a suspected drug allergy
should include a detailed history of all prescription and
nonprescription drugs taken by the patient, including
dates of administration, drug formulation, dosage and
route of administration, clinical symptoms and their
timing and duration in relation to drug exposure; as
well as previous drug exposures and reactions [1,4,6,15].
Clinical presentation
In addition to the detailed history, a careful physical
examination can help to define possible mechanisms
underlying the reaction and guide subsequent investiga-
tions and diagnostic testing. Table 4 highlights some of
the most common clinical manifestations of drug allergy
and examples of causative drugs.
T h es k i ni st h eo r g a nm o s tf r e q u e n t l ya n dp r o m i -
nently affected by drug-induced allergic reactions
[1,6,11]. The most common cutaneous manifestation is
generalized exanthema (also known as a maculopapular
rash), which is characterized by raised, spotted lesions
that appears within days to 3 weeks after drug exposure,
originate on the trunk, and eventually spread to the
limbs. Urticaria (hives) and angioedema (swelling) are
also common, and can results from both IgE-mediated
and non-IgE-mediated mechanisms. The most severe
forms of cutaneous drug reactions are Stevens-Johnson
syndrome (SJS) and toxic epidermal necrolysis (TEN).
SJS begins with a maculopapular rash that often pro-
gresses to bullae, mucous membrane ulcerations, con-
junctivitis, fever, sore throat and fatigue. TEN is a rare
condition with similar characteristics to SJS, but it also
causes large portions of the epidermis (the skin’s outer-
most layer) to detach from the layers below, leading to
extensive skin sloughing and a scalded skin appearance.
Given the severity of these conditions, drugs suspected
of causing SJS and TEN (most commonly sulfonamides)
should be strictly avoided by the patient in the future
[1].
Although skin reactions are the most common physi-
cal manifestation of drug-induced allergic reactions,
many other organ systems may be involved, such as the
renal, hepatic and hemolytic systems (see Table 4).
Multi-organ reactions may also occur and include ana-
phylaxis (a serious systemic allergic reaction that is
rapid in onset and may cause death; see Anaphylaxis
article in this supplement), drug rash with eosinophilia
and systemic symptoms (DRESS) syndrome, serum sick-
ness, drug-induced lupus erythematosus (DILE) and vas-
culitis (a heterogeneous group of disorders that are
characterized by inflammatory destruction of blood ves-
sels). DRESS is a potentially life-threatening condition
characterized by a widespread rash, fever, lymphadeno-
pathy (swollen/enlarged lymph nodes) and hepatic dys-
function. Serum sickness is an immune-complex
reaction that presents with fever, lymphadenopathy,
arthralgia, and cutaneous lesions. The typical symptoms
of DILE include sudden onset of fever and malaise;
myalgia, arthralgia, and arthritis may also occur several
weeks after drug initiation. In approximately 25% of
cases, the skin may also be affected [1,11]. Serum sick-
ness and DILE are usually self-limited, with symptoms
resolving spontaneously within a few weeks after discon-
tinuation of the offending drug. However, the symptoms
of DRESS may worsen or persist for weeks, or even
months, following drug discontinuation [1,11].
Since the clinical manifestations of drug allergy are
highly variable, it is important to exclude other condi-
tions that may mimic drug-induced allergic reactions.
Table 5 lists some of the conditions that should be con-
sidered in the differential diagnosis of drug allergy.
Diagnostic tests
Skin testing procedures, such as skin prick testing (SPT)
and intradermal tests (test in which the allergen is
injected into the skin dermis) are useful for the
Table 3 Risk factors for the development of drug allergy
[15]
￿ Patient-related factors:
￿ Age: young/middle-aged adults > infants/elderly
￿ Gender: Women > men
￿ Genetic polymorphisms
￿ Viral infections: HIV, herpes viruses
￿ Previous reaction to the drug
￿ Drug-related factors:
￿ High molecular weight compounds and hapten-forming drugs are
more immunogenic
￿ Route: topical > intravenous/intramuscular > oral
￿ Dose: frequent/prolonged > single dose
HIV: human immunodeficiency virus
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protocols are standardized for penicillin, and are also
useful (but rarely positive) for local anesthetics, muscle
relaxants, and very sensitive for high-molecular-weight
protein substances, such as insulin or monoclonal anti-
bodies. Positive skin tests to these drugs confirm the
presence of antigen-specific IgE and supports the
diagnosis of a type I hypersensitivity reaction. The nega-
tive predictive value of penicillin skin testing is high
with appropriate reagents and, therefore, a negative test
result is useful for ruling out penicillin allergy. With
other agents (except high molecular weight proteins),
however, a negative skin test does not effectively rule
out the presence of specific IgE. Serum-specific IgE tests
Table 4 Clinical manifestations of drug allergy. [1,11,15]
Manifestation Clinical Features Examples of causative drugs
Skin
Exanthemata ￿ Diffuse, fine macules and papules
￿ Evolve over days post drug initiation
Allopurinol, penicillins, cephalosporins, anticonvulsants, sulfonamides
Urticaria,
angioedema
￿ Onset within minutes to hours of drug administration
￿ Potential for anaphylaxis
￿ Often IgE-mediated
Antibiotics, ACE inhibitors, anticonvulsants, neuromuscular blocking
agents, platinums, radiocontrast media, NSAIDs, narcotics
Fixed drug
eruption
￿ Hyper-pigmented plaques that occur at the same site
upon re-exposure to the culprit drug
Sulfonamide and tetracycline antibiotics, NSAIDs, ASA, sedatives,
chemotherapeutic agents, anticonvulsants
SJS ￿ Fever, sore throat, fatigue, ocular involvement
￿ Ulcers and other lesions on mucous membranes,
particularly of the mouth and lips, as well as on truncal
area
Sulfonamides, nevirapine, corticosteroids, anticonvulsants, NSAIDs
(oxicams), allopurinol, phenytoin, carbamazepine, lamotrigine,
barbiturates, psychotropic agents, pantoprazole, tramadol
TEN ￿ Similar to SJS, but usually involves significant epidermal
detachment
￿ Potentially life-threatening
Same as SJS
Hematologic ￿ Hemolytic anemia, leukopenia, thrombocytopenia Penicillin, sulfonamides, anticonvulsants, cephalosporins, quinine,
heparin, thiazides, gold salts
Hepatic ￿ Hepatitis, cholestatic jaundice Sulfonamides, phenothiazines, carbamazepine, erythromycin, anti-
tuberculosis agents, allopurinol, gold
Renal ￿ Interstitial nephritis, glomerulonephritis Penicillin, sulfonamides, allopurinol, PPIs, ACE inhibitors, NSAIDs
Multi-organ
reactions
Anaphylaxis
￿ Urticaria/angioedema, bronchospasm, gastrointestinal
symptoms, hypotension
Antibiotics, neuromuscular blocking agents, anesthetics, radiocontrast
media, recombinant proteins (e.g., omalizumab)
DRESS ￿ Cutaneous eruption, fever, eosinophilia, hepatic
dysfunction, lymphadenopathy
Anticonvulsants, sulfonamides, minocycline, allopurinol, strontium
ranelate
Serum
sickness
￿ Urticaria, arthralgias, fever Heterologous antibodies, infliximab, allopurinol, thiazides, antibiotics (e.
g., cefaclor) and bupropion
DILE ￿ Arthralgias, myalgias, fever, malaise Hydralazine, procainamide, isoniazid, quinidine, minocycline, antibiotics,
and anti–TNF-alpha agents
Vasculitis ￿ Cutaneous or visceral vasculitis Sulfonamide antibiotics and diuretics, hydralazine, penicillamine,
propylthiouracil
ACE: angiotensin-converting enzyme; NSAIDs: non-steroid anti-inflammatory drugs; SJS: Stevens-Johnson syndrome; TEN: toxic epidermal necrolysis; DRESS: Drug
rash with eosinophilia and systemic symptoms; DILE: drug-induced lupus erythematosus; ASA: acetylsalicylic acid; PPIs: proton pump inhibitors; TNF: tumour
necrosis factor
Table 5 Conditions to consider in the differential diagnosis of drug allergy. [5]
IgE-mediated drug allergy
(urticaria, angioedema, anaphylaxis, bronchospasm):
￿ Carcinoid syndrome
￿ Insect bites/stings
￿ Mastocytosis
￿ Asthma
￿ Food allergy
￿ Scombroid fish poisoning
￿ Latex allergy
￿ Infection (EBV, hepatitis A, B, C, gastrointestinal parasites)
Non-IgE mediated reactions
(exanthema, DRESS, SJS, TEN):
￿ Acute graft-versus-host disease
￿ Kawasaki disease
￿ Still’s disease
￿ Psoriasis
￿ Insect bites/stings
￿ Viral infection
￿ Streptococcal infection
IgE: immunoglobulin E; EBV: Epstein-Barr virus; SJS: Stevens-Johnson syndrome; TEN: toxic epidermal necrolysis; DRESS: Drug rash with eosinophilia and systemic
symptoms
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these tests are costly and generally less sensitive than
skin tests. Furthermore, most of these in vitro tests are
not adequately validated for drug allergy testing [1,15].
Patch testing involves placing potential allergens (at
non-irritant concentrations) on the patient’s back for 48
hours under aluminum discs, and then assessing for
reactions. Drug patch testing is useful for the diagnosis
of various delayed (type IV) cutaneous reactions, parti-
cularly exanthemata, but is generally not helpful for the
diagnosis of SJS or TEN [1,10,11,15,16].
The measurement of histamine and tryptase levels
have proved useful in confirming acute IgE-mediated
reactions, particularly anaphylaxis; however, negative
results do not rule out acute allergic reactions. A com-
plete blood count can help diagnose hemolytic (type II)
drug-induced reactions, such as hemolytic anemia,
thrombocytopenia, or neutropenia. Hemolytic anemia
may also be confirmed with a positive direct and/or
indirect Coombs’ test (used to examine for the presence
of antibodies on red blood cell membranes) [1,11,15].
Recent studies have focused on the potential role of
the basophil activation test (the quantification of baso-
phil activation by flow cytometry) in the diagnosis of
drug allergy, since basophils are involved in both
immune-mediated and non-immune-mediated reactions.
Although some evidence suggests that the test is useful
for evaluating possible allergies to beta-lactam antibio-
tics, NSAIDs and muscle relaxants, further confirmatory
studies are needed before it is widely accepted as a diag-
nostic tool [1,17,18].
In cases where there is a definite medical need for a
particular drug, but the clinical diagnosis of drug allergy
remains uncertain despite thorough investigations, a
procedure to induce temporary drug tolerance (also
referred to as drug desensitization) or graded challenge
testing (also known as provocation testing) may be con-
sidered. Induction of drug tolerance procedures tem-
porarily modify a patient’s immunologic or non-
immunologic response to a drug through the adminis-
tration of incremental doses of the drug. Most regimens
begin with a very dilute concentration of the drug, and
the dose is doubled every 15 to 20 minutes, until a full
therapeutic dose has been administered after 3 to 8
hours. Drug tolerance is usually maintained only as long
as the drug is administered; the procedure needs to be
repeated in the future if the patient requires the drug
again after finishing a prior therapeutic course. Unlike
induction of drug tolerance procedures, graded chal-
lenge tests do not modify a patient’s immunologic or
non-immunologic response to a given drug. These tests
are generally used to determine whether a patient will
have an adverse reaction to a particular drug by admin-
istering sub-therapeutic doses over a period of time,
while observing the patient for potential reactions. They
are not advised if the patient has experienced a previous
life-threatening reaction to the drug in question. Drug
tolerance-induction procedures and graded challenges
are potentially harmful and should only be performed
by experienced personnel in facilities with resuscitative
equipment readily available [1,19].
Management of common drug allergies
The most effective strategy for the management of drug
allergy is avoidance or discontinuation of the offending
drug. When available, alternative medications with unre-
lated chemical structures should be substituted. Cross-
reactivity among drugs should be taken into considera-
tion when choosing alternative agents [1,11].
Additional therapy for drug hypersensitivity reactions
is largely supportive and symptomatic. For example,
topical corticosteroids and oral antihistamines may
improve cutaneous symptoms. In the event of anaphy-
laxis, the treatment of choice is epinephrine adminis-
tered by intramuscular injection into the lateral thigh.
Systemic corticosteroids may also be used to treat severe
systemic reactions, but should never be given prior to or
replace epinephrine in the treatment of anaphylaxis.
Severe drug reactions, such as SJS and TEN, are best
treated in an intensive care or burn unit setting [1,11].
Strategies for the management of some of the most
common drug allergies are discussed below.
Penicillin
Penicillin is the most frequent drug allergy, affecting
approximately 10% of patients. For patients with penicil-
lin allergy, treatment is best limited to non-penicillin
agents. Carbapenems (e.g., imipenem) do not exhibit a
significant degree of cross-reactivity with penicillin and
may be administered as a graded challenge after prophy-
lactic skin tests with the relevant carbapenem [20,21].
Monobactams, such as aztreonam, are generally well tol-
erated by patients with penicillin allergy, except if they
had an allergic reaction to ceftazidime [22-24]. Second-
or third-generation cephalosporins may also be consid-
ered since the degree of cross reactivity with these
agents and penicillin has been shown to be lower than
with first-generation agents (see following Cephalos-
porin section) [1,25].
Ideally, management of the patient with penicillin
allergy should include penicillin skin testing. Approxi-
mately 90% of patients have negative penicillin skin test
responses and can safely receive cephalosporins as well
as other beta-lactam agents. If a penicillin is deemed
absolutely necessary in a penicillin-allergic patient,
desensitization should be considered, and the procedure
should only be performed under medical supervision in-
hospital [1].
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Sulfonamide antibiotics are another common cause of
drug-induced allergic reactions, and are often associated
with delayed cutaneous maculopapular eruptions, SJS
and TEN. Patients infected with HIV are at increased
risk of developing cutaneous reactions to sulfonamide
antibiotics, which is likely related to immunologic fac-
tors and frequent exposure to these antibiotics. Tri-
methoprim-sulfamethoxazole (TMP-SMX) is the drug of
choice for the treatment of a number of HIV-associated
infections and, therefore, many HIV-positive patients
with a history of reacting to sulfonamides still require
treatment with this antibiotic. Induction of drug toler-
ance procedures can be used to safely administer TMP-
SMX to HIV-positive patients with a history of reacting
to the antibiotic.
Since the chemical structure of non-antibiotic sulfona-
mides (e.g., thiazide diuretics, some NSAIDs and antic-
onvulsants) varies from sulfonamide antibiotics, these
agents are not expected to cross-react, and can generally
be safely administered to patients with a history of
allergy to sulfonamide antibiotics. An exception is sulfa-
salazine which, by intestinal degradation becomes sulfa-
pyridine, acquiring an aromatic immunogenic structure
like sulfamethoxazole [1,26-28].
Cephalosporins
The most common allergic reactions to cephalosporins
are maculopapular rashes and drug fever; urticaria is
less common and anaphylaxis is rare [25]. As mentioned
earlier, positive skin tests to penicillin are associated
with a higher likelihood of allergic reactions to first-gen-
eration cephalosporins. In these patients, alternate
agents should be considered. In cephalosporin allergic
subjects, there is limited cross reactivity on immunologi-
cal testing between second- and third-generation cepha-
losporins and penicillins, especially amino-penicillins,
but this has not necessarily indicated clinical reactivity
[29]. There is a role for skin testing with the proposed
antibiotic to be used in therapy, and/or administration
by graded challenge. If skin testing is positive and no
alternative drug exists, induction of drug tolerance pro-
cedures may be attempted [1,5].
Radiocontrast media
Radiocontrast media (RCM) are associated with both
allergic and pseudoallergic reactions. The incidence of
reactions to RCM, including severe, life-threatening
reactions, appears to be lower with non-ionic versus
ionic agents. Pseudo/allergic reactions to RCM can
usually be prevented through the use of pretreatment
regimens that include oral corticosteroids and H1-anti-
histamines. Low osmolarity agents should also be used
in such circumstances [1,5].
Local anesthetics
True allergic reactions to local anesthetics (e.g., novo-
caine, lidocaine) are extremely rare; reactions are usually
due to other ingredients in the medication, such as pre-
servatives or epinephrine. However, if the reaction his-
tory is consistent with a possible immediate, IgE-
mediated (type I) reaction, skin testing followed by
graded challenge tests using epinephrine-free, preserva-
tive-free local anesthetics may be utilized [1].
General anesthetics
Although rare, anaphylaxis may occur in patients under
general anesthesia. The investigation of severe reactions
during general anesthesia is particularly challenging
given that the patient is often exposed to many co-
administered drugs and agents. Reactions during general
anesthesia are often due to neuromuscular blocking
agents, but have also been associated with intravenous
anesthetics (e.g., propofol, thiopentone, etomidate), anti-
biotics, NSAIDs and latex allergy. There are no reported
cases of allergy to inhaled anesthetics. Assessment by an
allergist is important for confirming the clinical diagno-
sis of allergy to general anesthesia, identifying likely cau-
sative agents as well as alternative agents that may be
used safely in the future [30].
Acetylsalicylic acid/NSAID reactions
Acetylsalicylic acid (ASA) and NSAIDs can cause both
true allergic and pseudoallergic reactions, including
exacerbations of underlying respiratory diseases, urti-
caria, angioedema, and anaphylaxis. Patients with under-
lying chronic respiratory diseases, such as asthma,
rhinitis and sinusitis, may react to ASA and NSAIDs
that inhibit cyclooxygenase-1 (COX-1). The manage-
ment of these patients involves avoidance of aspirin and
NSAIDs and aggressive treatment of the underlying
respiratory disorder. Selective COX-2 inhibitors almost
never cause reactions, and can typically be taken safely
by patients with ASA/NSAID allergy. An induction of
drug tolerance procedure to aspirin (also known as
aspirin desensitization) may also be considered [1].
Patients with chronic urticaria/angioedema generally
tolerate COX-2 inhibitors, but may experience exacerba-
tions of urticaria/angioedema with NSAIDs that inhibit
COX-1. True allergic reactions to NSAIDs are usually
drug specific and, therefore, patients experiencing these
reactions are often able to tolerate other NSAIDS [1].
Prevention of future reactions
Prevention of future reactions is an essential part of
patient management. The patient should be provided
with written information about which drugs to avoid
(including over-the-counter medications). The drugs
should be highlighted in the hospital notes and within
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family physician should be informed of the drug allergy.
Engraved allergy bracelets/necklaces, such as those pro-
vided by Medic Alert, should also be considered, parti-
cularly if the patient has a history of severe drug-
induced allergic reactions [15].
Conclusions
Drug allergy is a common clinical problem; assessment
by an allergist is important for appropriate diagnosis
and management of the condition. Diagnosis relies on a
careful history and physical examination and, in some
instances, skin testing, graded challenges and induction
of drug tolerance procedures may be required. The
mainstay of treatment for drug allergy is avoidance of
the offending drug. When available, alternative medica-
tions with unrelated chemical structures should be sub-
stituted. Cross-reactivity among drugs should be taken
into consideration when choosing alternative medica-
tions. If a particular drug to which the patient is allergic
is indicated and there is no suitable alternative, induc-
tion of drug tolerance procedures may be considered to
induce temporary tolerance to the drug.
Key take-home messages
￿ Drug allergy encompasses a spectrum of immunologi-
cally mediated hypersensitivity reactions with varying
mechanisms and clinical presentations.
￿ Risk factors for drug allergy include age (more com-
mon in young/middle-aged adults), gender (more com-
mon in females), genetic polymorphisms, certain viral
infections (HIV and herpes viruses) and drug-related
factors (topical and intravenous/intramuscular routes of
administration are more immunogenic than oral
administration).
￿ Referral to an allergist is important for appropriate
diagnosis and treatment of drug allergy.
￿ Diagnosis requires a thorough drug history, includ-
ing dates of administration, drug formulation, dosage
and route of administration, as well as clinical symp-
toms and their timing and duration in relation to drug
exposure; skin testing, graded challenges and induction
of drug tolerance procedures may also be required.
￿ T h es k i ni st h eo r g a nm o s tf r e q u e n t l ya f f e c t e db y
drug-induced allergic reactions, however, many other
organ systems may be involved, including multi-organ
reactions such as anaphylaxis.
￿ The mainstay of treatment is avoidance of the
offending drug; alternative medications with unrelated
chemical structures should be substituted when possible.
￿ If a particular drug to which the patient is allergic is
indicated, induction of drug tolerance procedures may
be considered to induce temporary tolerance to the
drug.
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